Trial Profile
Evaluation of plasma angiotensinogen(AGT) and the effect of DRI on AGT and RAAS in hemodialysis patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- 06 Oct 2011 New trial record